Evidence Mounts that RAS-Blocking Medications Pose No Danger to COVID-19 Patients

Restricted access

Many professional societies staked out the early position that COVID-19 patients should continue their blood pressure medications in the absence of a clear reason to stop them. And the early evidence to date has reinforced those recommendations.

It will take at least several months for more definitive answers from clinical trials, but the three largest observational studies to date found no signals of harm among patients taking inhibitors of the renin-angiotensin system (RAS) pathway.

Published in the May 1, 2020, New England Journal of Medicine, the studies are ‚Äúdefinitely the biggest and most authoritative‚ÄĚ so far, said Matthew